BiotechTube

Erlotinib + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Oral Cancer

Conditions

Oral Cancer

Trial Timeline

Nov 3, 2006 → Jun 4, 2018

NCT ID
NCT00402779

About Erlotinib + Placebo

Erlotinib + Placebo is a phase 3 stage product being developed by Astellas Pharma for Oral Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00402779. Target conditions include Oral Cancer.

What happened to similar drugs?

5 of 20 similar drugs in Oral Cancer were approved

Approved (5) Terminated (2) Active (14)
❌AL001 + Placebo + Open label - AL001AlectorPhase 3
🔄Micafungin + FluconazoleAstellas PharmaPhase 3
🔄micafungin + caspofunginAstellas PharmaPhase 3
✅AmifostineSun PharmaceuticalApproved
🔄Teriparatide 20 mcgEli LillyPhase 3
✅tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved
✅Essential oils + 0.2% chlorhexidine + Sterile waterJohnson & JohnsonApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00402779Phase 3Completed
NCT00373425Phase 3Completed

Competing Products

20 competing products in Oral Cancer

See all competitors
ProductCompanyStageHype Score
AL001 + Placebo + Open label - AL001AlectorPhase 3
22
AL001AlectorPhase 2
25
AG013OragenicsPhase 2
17
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
29
Micafungin + FluconazoleAstellas PharmaPhase 3
40
micafungin + caspofunginAstellas PharmaPhase 3
40
AmifostineSun PharmaceuticalApproved
35
exenatide + Other antidiabetic therapiesEli LillyPre-clinical
26
Teriparatide 20 mcgEli LillyPhase 3
40
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional PrednisoneEli LillyPhase 1/2
36
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
39
tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved
43
Essential oils + 0.2% chlorhexidine + Sterile waterJohnson & JohnsonApproved
43
galantamine hydrobromideJohnson & JohnsonPhase 2
35
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
40
Camrelizumab + Camrelizumanb plus TPFJiangsu Hengrui MedicinePhase 2
35
Camrelizumab plus TP + TPJiangsu Hengrui MedicinePhase 3
47
AZD1981 + Neovletta 21/28 + Placebo AZD1981AstraZenecaPhase 1
29
DurvalumabAstraZenecaPhase 1/2
36
fostamatinib + Microgynon® 30 (Oral contraceptive) + PlaceboAstraZenecaPhase 1
29